TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21990056

Group type: EXPERIMENTAL
Intervention: Vertical vibrating, 35 Hz, 1.7 mm (VG)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rotational vibrating 12.5 Hz, 12 mm (RG)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Low intensity gymnastic and relaxation program (Control Group)
Number of subjects: 108
Study: 18472670

Group type: EXPERIMENTAL
Intervention: Substance abuse treatment for rural adolescents
Number of subjects: 404

Group type: COMPARATOR
Intervention: Substance abuse treatment for urban adolescents
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Substance abuse treatment for both groups
Number of subjects: 404
Study: 17006323

Group type: EXPERIMENTAL
Intervention: Cyclosporin microemulsion (CsA)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 129

Group type: COMPARATOR
Intervention: Healthy control subjects (CTL)
Number of subjects: 129
Study: 12571666

Group type: EXPERIMENTAL
Intervention: fortified diet - usual diet plus 100 microg/day folic acid from fortified foods
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: natural folate diet - usual diet plus 100 microg/day folate from natural sources
Number of subjects: 135

Group type: COMPARATOR
Intervention: control - usual diet
Number of subjects: 135
Study: 11138438

Group type: EXPERIMENTAL
Intervention: Community-based intervention consisting of six 90-minute sessions focusing on media literacy and advocacy skills.
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 226
Study: 9020555

Group type: EXPERIMENTAL
Intervention: Chemotherapy in patients with various tumors (lung cancers, lymphomas, and others)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Local radiotherapy in female patients with cervical or endometrial carcinoma
Number of subjects: 66
Study: 1399993

Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGF2 alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (citric acid)
Number of subjects: 0
Study: 4044466

Group type: EXPERIMENTAL
Intervention: Vibunazole 400 mg tablets administered alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vibunazole 400 mg tablets administered after 400 mg cimetidine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vibunazole 400 mg tablets administered after 30 ml diluted hydrochloric acid
Number of subjects: 6
Study: 31687165

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) group intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Behavioural Weight-Loss (BWL) intervention
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both ACT and BWL groups
Number of subjects: 88
Study: 28962842

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse (no preparation)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-etch (no preparation)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse with dentin roughening (ER+RO)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-etch with dentin roughening (SE+RO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study: 27253174

Group type: EXPERIMENTAL
Intervention: Ghrelin (0.5 μg kg(‐1) h(‐1)) for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 40
Study: 25201815

Group type: EXPERIMENTAL
Intervention: cPMd modulation (1-Hz rTMS)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: cM1 modulation (1-Hz rTMS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 44
Study: 21383086

Group type: EXPERIMENTAL
Intervention: 12-week interruption of ART
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART intensification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: No interruption of ART
Number of subjects: 0
Study: 20172327

Group type: EXPERIMENTAL
Intervention: Everolimus (target blood level, 3‐8 ng/mL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Azathioprine (2.0‐2.5 mg/kg/d)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 22

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 18308419

Group type: EXPERIMENTAL
Intervention: VNR 25mg/m² on day 1, 8 and 15 plus CDDP 100mg/m² on day 1 every 4 weeks
Number of subjects: 278

Group type: COMPARATOR
Intervention: VNR 30 mg/m² on day 1 and 8 plus CDDP 80 mg/m² on day 1 every 3 weeks
Number of subjects: 278
Study: 16095419

Group type: EXPERIMENTAL
Intervention: Group SC (n = 11) - climbed up and down stairs
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group ES (n = 11) - practiced electrostimulation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group SC + ES (n = 10) - superimposed climbing stairs and electrostimulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 32
Study: 11821466

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT) with five doses of 5 Gy
Number of subjects: 1530

Group type: COMPARATOR
Intervention: TME surgery alone
Number of subjects: 1530
Study: 11180567

Group type: EXPERIMENTAL
Intervention: Predicted scores derived from patients' responses using the EuroQol instrument's visual analogue scale.
Number of subjects: 649

Group type: COMPARATOR
Intervention: Predicted scores derived from the general public's responses to the EuroQol instrument.
Number of subjects: 649
Study: 9204057

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg twice a day
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Ranitidine 600 mg twice a day
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 8516421

Group type: EXPERIMENTAL
Intervention: Bright light intervention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no bright light)
Number of subjects: 17
Study: 3089123

Group type: EXPERIMENTAL
Intervention: 50% medium chain triglycerides (MCT)/50% long chain triglycerides (LCT) mixture
Number of subjects: 13

Group type: COMPARATOR
Intervention: long chain triglyceride emulsion (LCT)
Number of subjects: 13
Study: 28422539

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (NIT) 140 mL daily for 3 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (NIT)
Number of subjects: 8
Study: 28531113

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Metformin plus Policaptil Gel Retard® (PGR)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (LGI diet only)
Number of subjects: 129
Study: 25965717

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 23260188

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including qualitative and quantitative assessment of barriers to alteplase use and additional support.
Number of subjects: 40823

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 40823
Study: 21539743

Group type: EXPERIMENTAL
Intervention: CURB65-A risk class I (CURB65 score 0-1 and ProADM ≤0.75 nmol/l)
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: CURB65-A risk class II (CURB65 score 2 and ProADM ≤1.5 nmol/l or CURB classes 0-1 and ProADM levels between 0.75-1.5 nmol/L)
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: CURB65-A risk class III (all other patients)
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Outpatient treatment for CURB65-A risk class I
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Short hospitalization for CURB65-A risk class II
Number of subjects: 1359
Study: 18456557

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no ketogenic diet)
Number of subjects: 145
Study: 16548938

Group type: EXPERIMENTAL
Intervention: Repeated Contact group (5 proactive calls in addition to usual care)
Number of subjects: 1457

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: Repeated Contact group
Number of subjects: 1457

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1457
Study: 14605970

Group type: COMPARATOR
Intervention: Flexible multiple daily insulin (FMDI) regimen
Number of subjects: 44
Study: 10722029

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CT examination (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CT examination without contrast-enhanced medium (Group B)
Number of subjects: 20
Study: 9364627

Group type: EXPERIMENTAL
Intervention: 50.4 Gy schedule (2 x 1.8 Gy/day to a total dose of 50.4 Gy)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 30 Gy schedule (2 x 2.5 Gy/day to a total dose of 30 Gy)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Historical control group (1 daily fraction of 3 Gy up to 30 Gy)
Number of subjects: 62
Study: 1542320

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg daily)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 30297018

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage reduction intervention
Number of subjects: 146

Group type: COMPARATOR
Intervention: Income-ineligible nonparticipants
Number of subjects: 146

Group type: COMPARATOR
Intervention: SNAP participants
Number of subjects: 146
Study: 25056532

Group type: COMPARATOR
Intervention: EPUFAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: EPUFAs and Vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25666957

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All patients and non-smokers
Number of subjects: 0
Study: 23106176

Group type: EXPERIMENTAL
Intervention: Conventional fractionation (2.0 Gy per day, total 68 Gy during 7 weeks)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Accelerated fractionation (1.1 + 2.0 Gy per day, total 68 Gy during 4.5 weeks)
Number of subjects: 712
Study: 21129235

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (1.48 g EPA+DHA/d) for 12 weeks
Number of subjects: 113

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 113
Study: 18665697

Group type: EXPERIMENTAL
Intervention: IE/IVE/CR
Number of subjects: 118

Group type: COMPARATOR
Intervention: IE
Number of subjects: 118

Group type: COMPARATOR
Intervention: IVE
Number of subjects: 118

Group type: COMPARATOR
Intervention: IE/IVE
Number of subjects: 118
Study: 16391155

Group type: EXPERIMENTAL
Intervention: Polymer-free, rapamycin-coated Yukon DES (rapamycin stent)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Polymer-based, paclitaxel-eluting Taxus stent (paclitaxel stent)
Number of subjects: 450
Study: 12732857

Group type: EXPERIMENTAL
Intervention: Minute Ventilation Test (MVT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clinical Judgement
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 10992830

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Patient-controlled i.v. morphine alone (control)
Number of subjects: 38
Study: 8787884

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg (normotensive)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Valaciclovir 1,000 mg (normotensive)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg (hypertensive)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Valaciclovir (all groups)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Valaciclovir (elderly)
Number of subjects: 29
Study: 1460154

Group type: EXPERIMENTAL
Intervention: Contingent methadone take-home privileges
Number of subjects: 53

Group type: COMPARATOR
Intervention: Noncontingent procedure
Number of subjects: 53

Group type: COMPARATOR
Intervention: Noncontingent procedure shifting to contingent procedure
Number of subjects: 53
Study: 3883493

Group type: EXPERIMENTAL
Intervention: Adriamycin administered at 6 p.m. followed by cisplatin at 6 a.m.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Adriamycin administered at 6 a.m. followed by cisplatin at 6 p.m.
Number of subjects: 31
Study: 30857184

Group type: EXPERIMENTAL
Intervention: FT-NIR spectroscopy with partial least discriminant analysis (PLS-DA) model
Number of subjects: 100
Study: 29719989

Group type: EXPERIMENTAL
Intervention: Abductive theory of method (ATOM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 0
Study: 27258524

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 1 μg/kg for 10 minutes, followed by continuous infusion at 0.5 μg/kg/h until 30 minutes before the end of surgery)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Saline (same volume as dexmedetomidine)
Number of subjects: 94
Study: 25037677

Group type: EXPERIMENTAL
Intervention: Type II diabetes mellitus group (DM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-diabetes mellitus group (non-DM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EAT volume >120 cm(3)
Number of subjects: 0
Study: 22664394

Group type: EXPERIMENTAL
Intervention: Composite meal (protein rich food, carbohydrate rich food, and vegetable)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Low carbohydrate meal (protein rich food and vegetable)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Vegetarian meal (carbohydrate rich food and vegetable)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Individual foods presentation (stir-fry or stew)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Composite meal (stir-fry or stew)
Number of subjects: 51
Study: 19845547

Group type: EXPERIMENTAL
Intervention: VR004 (apomorphine) 100-300 microg
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 16523157

Group type: EXPERIMENTAL
Intervention: Prolate aspherical IOL (TECNIS Z9000, AMO, USA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spherical IOL (911 CeeOn Edge, AMO, USA)
Number of subjects: 20
Study: 15249568

Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Number of subjects: 602

Group type: COMPARATOR
Intervention: Stavudine
Number of subjects: 602
Study: 11110739

Group type: EXPERIMENTAL
Intervention: Problem solving treatment (n=128)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Prevention of depression (n=108)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group (n=189)
Number of subjects: 452
Study: 9314468

Group type: EXPERIMENTAL
Intervention: Anti-HAV detection in IDUs
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Anti-HAV detection in homosexual males
Number of subjects: 900

Group type: COMPARATOR
Intervention: Anti-HAV detection in blood donors
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Association of anti-HAV with socioeconomic status in IDUs
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Association of anti-HAV with number of sexual partners in homosexual males
Number of subjects: 900

Group type: COMPARATOR
Intervention: Comparison of anti-HAV prevalence with general population
Number of subjects: 900
Study: 8310852

Group type: EXPERIMENTAL
Intervention: L-sulpiride
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 30
Study: 3017174

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30868938

Group type: EXPERIMENTAL
Intervention: Warmed and humidified CO2 insufflation with HumiGard device, plus hot air warming blanket (H + WB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard CO2 insufflation, plus hot air warming blanket (WB)
Number of subjects: 64
Study: 28403084

Group type: EXPERIMENTAL
Intervention: Gabapentin plus vitamin B complex (group GB)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Gabapentin alone (group G)
Number of subjects: 128
Study: 26254845

Group type: EXPERIMENTAL
Intervention: High-dose carotenoid-rich juice (2.75 mg carotenoids/30 mL juice)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low-dose carotenoid-rich juice (2.75 mg carotenoids/30 mL juice)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 58
Study: 23504666

Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention (geriatric consultation, continuous rehabilitation, discharge planning)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 160
Study: 22364094

Group type: EXPERIMENTAL
Intervention: Normal saline (0.9% NaCl) irrigation with sequential irrigation of 3% H2O2, 5.2% NaOCl and 0.9% NaCl
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied to be the other treatment group)
Number of subjects: 104
Study: 19095827

Group type: EXPERIMENTAL
Intervention: 6% HES200/0.5 or 6% HES130/0.4
Number of subjects: 45

Group type: COMPARATOR
Intervention: 4% human albumin solution
Number of subjects: 45
Study: 17005272

Group type: EXPERIMENTAL
Intervention: Simvastatin (20-40 mg/day) for 8 weeks
Number of subjects: 76
Study: 15775796

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 70

Group type: COMPARATOR
Intervention: Losartan vs Atenolol
Number of subjects: 70
Study: 12411457

Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg/d
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no canrenone)
Number of subjects: 34

Group type: COMPARATOR
Intervention: ACE inhibitors and calcium antagonists (baseline treatment)
Number of subjects: 34
Study: 9857348

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (IFN-alpha 2a)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: (re)treatment during long-term follow-up
Number of subjects: 469

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 469
Study: 8580556

Group type: EXPERIMENTAL
Intervention: Continuous injection of isosorbide dinitrate (ISDN) at 10 mg/h
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intermittent injection of isosorbide dinitrate (ISDN) at 10 mg/10 min every 2 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both continuous and intermittent ISDN
Number of subjects: 22
Study: 2213778

Group type: EXPERIMENTAL
Intervention: 80 micrograms triiodothyronine (T3) daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 362282

Group type: EXPERIMENTAL
Intervention: Vitamin A therapy (vitamin A palmitate or 13‐cis vitamin A acid)
Number of subjects: 9
Study: 31009064

Group type: EXPERIMENTAL
Intervention: ANCOVA adjustment in randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear model for outcome given treatment arm and baseline variables
Number of subjects: 0
Study: 27897461

Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL) group
Number of subjects: 8

Group type: COMPARATOR
Intervention: Early Loading (EL) group
Number of subjects: 8
Study: 26092545

Group type: EXPERIMENTAL
Intervention: Danirixin 50 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Danirixin 100 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Danirixin 200 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Danirixin with food
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Danirixin 100 mg with omeprazole 40 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Danirixin in elderly subjects
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23459487

Group type: EXPERIMENTAL
Intervention: 100 mg bedaquiline
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 200 mg bedaquiline
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 300 mg bedaquiline
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 400 mg bedaquiline
Number of subjects: 68
Study: 21807781

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) monotherapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) monotherapy
Number of subjects: 64
Study: 19537862

Group type: EXPERIMENTAL
Intervention: Octenidine dihydrochloride (OCT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate (CHX)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Polyvinylpyrrolidone‐iodine complex (PVP‐I)
Number of subjects: 18
Study: 16765798

Group type: EXPERIMENTAL
Intervention: 2-site phacotrabeculectomy
Number of subjects: 130

Group type: COMPARATOR
Intervention: 1-site phacotrabeculectomy
Number of subjects: 130
Study: 15001964

Group type: EXPERIMENTAL
Intervention: Oral sustained‐release morphine, 1.9 mg/kg every 12 hours
Number of subjects: 15

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of morphine at 0.04 mg/kg/hour
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral sustained‐release morphine
Number of subjects: 15
Study: 11417848

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisone for 8 weeks (Control)
Number of subjects: 20
Study: 9754724

Group type: EXPERIMENTAL
Intervention: Contact with pigs
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Contact with cats
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Contact with dogs
Number of subjects: 662

Group type: COMPARATOR
Intervention: H. pylori infection
Number of subjects: 662
Study: 7918140

Group type: EXPERIMENTAL
Intervention: Quinapril (5-40 mg qd for MRI; 2.5-20 mg qd for CRF)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 2561750

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) administered at one 7500, 15000 or 30000 AXaU vial/day sc for 60 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Heparin calcium administered at one or two 12500 IU vials/day sc for 60 days
Number of subjects: 60